Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765892 | 0.87 | BACE1 (0.37) | BACE1OPRL1OPRK1OPRM1BACE2 | |
| SCHEMBL3892756 | 0.84 | BACE1 (0.37) | BACE1OPRL1OPRD1OPRK1OPRM1 | |
| SCHEMBL3491947 | 0.84 | BACE1 (0.37) | BACE1OPRL1OPRD1OPRK1OPRM1 | |
| SCHEMBL3494036 | 0.83 | BACE1 (0.40) | BACE1OPRL1OPRD1OPRK1OPRM1 | |
| SCHEMBL3494038 | 0.83 | BACE1 (0.40) | BACE1OPRL1OPRD1OPRK1OPRM1 | |
| SCHEMBL3494202 | 0.83 | BACE1 (0.34) | BACE1OPRL1OPRM1BACE2 | |
| SCHEMBL13359099 | 0.82 | OPRM1 (0.37) | BACE1OPRL1OPRK1OPRM1BACE2 | |
| SCHEMBL3493505 | 0.82 | BACE1 (0.38) | BACE1HRH3 | |
| SCHEMBL764691 | 0.81 | ADORA3 (0.40) | BACE1OPRL1OPRD1OPRK1OPRM1 | |
| SCHEMBL760030 | 0.80 | BACE1 (0.34) | BACE1OPRL1OPRD1OPRM1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | BACE1 1/4885OPRL1 2101/4885OPRD1 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.